Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
Adaptive Biotechnologies reported Q2 2026 revenue of $71.6 million, up 22% year-over-year with MRD segment revenue growing 33%. The company achieved strong clinical test volume growth, enhanced financial flexibility through a convertible notes offering, and announced plans to separate its MRD and Immune Medicine businesses. Updated full-year MRD re…